Cognition Therapeutics Inc (CGTX) · Nov 5, 2026 · Earnings

Cognition Therapeutics earnings beat, but Nasdaq flags $1 bid risk

Beat — EPS $(0.04) vs ~$0.07 loss consensus

Cognition Therapeutics’ earnings beat the published loss estimate, but a new Nasdaq bid-price deficiency adds a separate financing and listing risk.

Cognition is a grant-supported, clinical-stage biotech advancing zervimesine toward a planned registrational DLB study while waiting for Phase 2 START Alzheimer’s results in the second half of 2027. Its prior quarter had already pointed to FDA alignment and a mid-2027 development path, so the clinical update is mainly execution detail rather than a wholly new strategic direction.

The quarter itself beat the limited published EPS benchmark. Cognition reported a $0.04 per-share loss versus an external consensus estimate of roughly $0.07, while the absolute loss narrowed from $4.9 million to $4.1 million year over year. The beat is real, but this is a pre-revenue biotech, so the operating result is less important than clinical progress and financing capacity.

Q3 2026Q3 2025Consensus
Net loss (Financial Highlights)$4.1M$4.9M
Diluted EPS (Financial Highlights)$(0.04)$(0.06)$(0.07)
R&D expense (Financial Highlights)$5.1M$3.8M
Cash and restricted cash (Balance Sheet)$31.5M$37.0M*
Cash runway (Business Update)Q4 2027

*December 31, 2025.

The pipeline is advancing, but the key clinical proof point remains distant. The company says FDA work produced a protocol for a planned registrational DLB study, with manufacturing, site selection and recruitment still under evaluation. START remains the larger Alzheimer’s catalyst, but topline data are not expected until the second half of 2027. 〔0〕 〔1〕

Funding looks adequate on the company’s stated plan, but the new Nasdaq deficiency is the filing’s most consequential surprise. Cash was $31.5 million, with $18.2 million of obligated grant funds remaining, and management estimates funding into the fourth quarter of 2027. However, the company disclosed that its bid price had stayed below $1.00 for 30 consecutive business days, giving it until May 3, 2027 to regain compliance. A second 180-day period may be available, but a reverse split could become necessary and delisting remains a stated risk.

Bottom line: The operating quarter modestly beat expectations and the drug program is moving forward, but those positives were largely incremental. The new Nasdaq compliance clock adds a material capital-markets and listing complication, making the overall filing mixed and slightly negative despite the EPS beat.

What to watch next

START topline results, second half of 2027

Original filing on SEC EDGAR

More Cognition Therapeutics Inc news

Cognition Therapeutics earnings beat, but Nasdaq flags $1 bid risk | CGTX Stock News
AllSight

Breaking down Wall Street's
information edge.

A buy-side analyst on every ticker — it reads every public company's filing the instant it drops and decodes it into plain English.

—
8-K events this week
—
filings analyzed in total
live · updated 30s ago
Live events · whole market · · --:--:-- ET
AllSight read
Straight from the 8-K
Verbatim from the filing AllSight decoded — highlighted above. Open on SEC EDGAR ↗
Limited-time offerFree 14-day Pro trial
AllSight

Sign in to AllSight

  • Follow any company — we email you the moment it files, free!
  • Your watchlist saved to your account, on every device — free!

by Signing in NOW, claim your FREE 14-day Pro trial!

No password. We email you a 6-digit code. By continuing you agree to our Terms & Privacy.
AllSight · Live plain-English 8-K decodes across the whole US market · Not investment advice.